Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

High-dose dexamethasone for refractory or relapsing multiple myeloma.

W R Friedenberg1, R A Kyle, W H Knospe

  • 1Department of Hematology, Marshfield Clinic, Wisconsin 54449.

American Journal of Hematology
|March 1, 1991
PubMed
Summary

High-dose dexamethasone monotherapy showed a 40% objective response rate in advanced cancer patients but caused significant toxicity. Maintenance therapy was well-tolerated, though further study is needed for remission induction efficacy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The WHO 2016 diagnostic criteria for Acute Myeloid leukemia with myelodysplasia related changes (AML-MRC) produce a very heterogeneous entity: A retrospective analysis of the FAB subtype RAEB-T.

Leukemia research·2021
Same author

A Case of Acute Eosinophilic Leukemia with a Novel <i>PHF</i>6 Mutation.

Case reports in hematology·2021
Same author

A case of Burkitt Leukemia: Revisiting the prognostic value of lactate dehydrogenase.

Leukemia research·2020
Same author

Application of a sequential multiple assignment randomized trial (SMART) design in older patients with chronic lymphocytic leukemia.

Annals of oncology : official journal of the European Society for Medical Oncology·2019
Same author

Publisher Correction: GloPL, a global data base on pollen limitation of plant reproduction.

Scientific data·2019
Same author

GloPL, a global data base on pollen limitation of plant reproduction.

Scientific data·2018

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • The VAD regimen (Vincristine, Adriamycin, Dexamethasone) is a standard treatment.
  • Assessing dexamethasone as a single agent is crucial for treatment optimization.

Purpose of the Study:

  • To evaluate the efficacy and toxicity of single-agent dexamethasone in advanced cancer.
  • To determine response rates, survival, and side effects of this monotherapy.

Main Methods:

  • An ECOG pilot study administered 40 mg oral dexamethasone daily for 4 days weekly for 8 weeks.
  • Patients achieving response were maintained on treatment every 2 weeks.
  • Efficacy and toxicity were assessed in evaluable patients.

Main Results:

  • 13/32 (40%) patients achieved objective responses; 8/28 (28.5%) had subjective responses.

Related Experiment Videos

  • 55% of patients experienced moderate to severe toxicity, including CNS effects, GI bleeding, and infections.
  • Median survival was 19 weeks (31 weeks for responders, 9 weeks for non-responders).

    • Conclusions:

    • High-dose dexamethasone monotherapy yields significant partial responses but is linked to excessive toxicity.
    • Maintenance therapy with less frequent dexamethasone administration was tolerated.
    • Further research is needed to establish the efficacy of dexamethasone monotherapy for remission induction.